Cost-effectiveness analysis has gained status over the last 15 years as an Abstract important tool for assisting resource allocation decisions in a budget-limited environment such as healthcare. Randomised (multicentre) multinational controlled trials are often the main vehicle for collecting primary patient-level information on resource use, cost and clinical effectiveness associated with alternative treatment strategies. However, trial-wide cost effectiveness results may not be directly applicable to any one of the countries that participate in a multinational trial, requiring some form of additional modelling to customise the results to the country of interest.
patient recruitment and large sample size, while search in the area of generalisability of CEA studies facilitating reimbursement submissions in several have been recently published by Reed et al., [12] jurisdictions. In fact, by recruiting participants from Sculpher et al. [7] and Goeree et al., [8] and the interdifferent countries (and settings), international ested reader is invited to refer to these reports for clinical studies are believed [7, 8] to offer the advan-further details. tage of generating evidence more likely to be
The present article discusses recent methodologi-'generalisable' across locations than that produced cal developments in the analysis of cost-effectiveby single-centre trials.
ness data collected alongside multicentre and mulIn spite of this, it has been argued that -strictly tinational randomised controlled trials (RCTs). The speaking -multinational trial-wide cost-effective-aim is to produce recommendations regarding methness results may not be directly applicable to any ods that can be (currently) considered 'good pracparticular one of the countries that participate in the tice' when exploring the geographical generalclinical study (or any other country for that mat-isability of cost-effectiveness data. We propose an ter), [9] requiring some form of additional modelling algorithm to assist with the choice of the appropriate to customise the results to a particular country 1 of analytical strategy when facing the task of adapting interest. [10] There are various reasons for this. Deci-the study results from one country to another. The sion makers are inherently country-specific and are algorithm considers different scenarios charactermore interested in results that are directly relevant to ised by whether the country of interest participated their own jurisdiction. Secondly, it is possible that in the trial and whether individual patient-level data the country of interest did not participate in the (IPD) from the trial are available. Given the other clinical trial. Thirdly, even when the country of articles in this conference issue of PharmacoEcointerest is part of the original study, the presence of nomics, [13] [14] [15] [16] [17] [18] [19] [20] [21] the article focuses, specifically, on the country-specific factors potentially affecting the ge-methods, and provides only a brief discussion of the ographical variability of the study results (effective-policy context. For a more detailed discussion of the ness, cost, and quality of life) means that trial-wide latter the reader is invited to refer to Sculpher and results may not be informative for reimbursement Drummond, [22] also included in this issue of decisions at the country level.
PharmacoEconomics. Bernie O'Brien was among the first to raise conThe manuscript is structured as follows. Section cerns [11] regarding the generalisability of CEA data 1 reviews the rationale for assessing the generalcollected in one country to inform reimbursement isability of cost-effectiveness results from country decisions in another. His seminal paper suggested to country, and summarises the current perception as that between-country differences in the following to which data can be directly 'applied' from one could all be potential threats: (i) demography and country to another and which need to be countryepidemiology of disease; (ii) clinical practice and specific. Section 2 presents the methodology used to conventions; (iii) incentives and regulations for produce country-specific estimates of cost effectivehealthcare providers; (iv) relative price levels; (v) ness distinguishing four main scenarios, characterconsumer preferences; and (vi) opportunity costs of ised by whether the country of interest participated resources. Health economists have attempted to ad-in the study and whether IPD from the trial are dress these concerns in many different ways since available. The implications for the design, data colthen, and, as methodology becomes more refined, lection, analysis and presentation of the study results new and alternative approaches are proposed. Three are considered next. The final section discusses fuextensive reviews of conceptual and applied re-ture lines of applied and policy research in this area.
1 The issue is the mismatch between the source of the data and the location of the decision maker. Thus, it could be argued that we should be referring to the 'jurisdiction of interest', where the term 'jurisdiction' encompasses both within-country (e.g. regions, provinces) and country-level decision makers.
International Variation in management of acute coronary syndrome (ACS). In Cost-Effectiveness Results
the latter clinical area, multinational RCTs found important between- [35, 36] and within-country [37] differences in resource use, therapeutic strategies and The globalisation of clinical research for short-term mortality. The same trend has been obpharmaceuticals and medical devices in many dis-served in many other clinical areas, [31, 32, [38] [39] [40] [41] specifiease areas (e.g. cardiovascular disease, oncology, cally with respect to variations in average length of respiratory disease), paired with the need of the stay when an identical treatment was implemented industry to seek regulatory approval in different in similar populations in several countries simultajurisdictions, mean that multinational trials are often neously. the preferred vehicle for primary (resource use, There are various factors that could affect the clinical and quality of life data) data collection. generalisability of the results of CEA studies. Geographical locations in North America, Western Sculpher et al. [7] reviewed the literature to identify Europe and Asia, traditionally chosen as a base from these factors and found 36 papers discussing potenwhich to recruit study participants, have now been tial sources of variability between locations. joined by countries in Latin America and Eastern Europe. Possible reasons behind this trend relate to
Patient Factors
the need to recruit even larger study samples, the expanding market for pharmaceuticals (and devices)
Patient-level variation feeds through to centre or in these geographical areas, and the less stringent country variations in cost effectiveness if patients' regulatory regimens operating in some countries.
characteristics (clinical and socio-demographic) are While increasing the potential for the conduct of not evenly distributed between locations. It can be large studies, the internationalisation of clinical repartly explained in terms of differences in demograsearch poses several challenges in terms of design, phy. [42] [43] [44] [45] [46] [47] [48] Variation between locations (e.g. centres management, statistical analysis and interpretation and countries) in the epidemiology of disease can of the study results. [23] In recognition of these chalalso translate onto different case-mixes between lolenges, the International Committee on Harmonisacations with obvious impact on the cost effectivetion (IHC) has developed a series of guidelines [24] [25] [26] [27] [28] ness of a given treatment in a specific locawith the objective of facilitating the conduct of tion. [45, 47, 49] international clinical studies, the expectation being that the evidence derived from these studies would be used to meet regulatory requirements in different 1.2 Clinician Factors jurisdictions. [23] One of the consequences of the globalisation of Clinicians can influence the effectiveness, cost clinical research, though, is that researchers are now and cost effectiveness of interventions. This 'clinimore aware of the existence of country and regional cian effect' is particularly important in non-drug variations in multinational trials with respect to re-interventions (e.g. surgical), but pharmaceutical trisource use and clinical outcome results. [29, 30] Be-als can also display between-clinician differences; tween-country variability in clinical effective-for instance, in background treatments given to paness, [31] resource use and quality of life results, [32] tients over and above the study treatment, or in the even after adjustment for patient baseline character-management of adverse events. The clinician effect istics, is a well known phenomenon in multinational is typically not easy to quantify within clinical [50] [51] [52] RCTs investigating the management of patients fol-or economic evaluations. [53, 54] In part, variation in lowing myocardial infarction, for instance. Similar how clinical staff perform can be because healthcare findings have been observed in studies considering systems also differ in terms of the incentives they patients' management after stroke, [33, 34] and the offer to staff. [11, 45, 47, [55] [56] [57] 1.3 Healthcare System Factors 1. What methods are there to make cost-effectiveness estimates more country-specific? There may be numerous differences between 2. How can we account for factors that may affect countries and centres [45, 47, 49, 56, [58] [59] [60] [61] [62] [63] [64] [65] (other than pa-the between-country generalisability of cost-effectient and clinician characteristics) in terms of the tiveness results? process of healthcare delivery. Between-country difIn broad terms, the analytical options available ferences in relative cost may be influenced by the range from the use of regression-based techniques to technology involved in the production of healthcare, the application of decision-analytic models, and are the level of substitution between labour and capital, already part of the toolkit of the health economist and the types and cost of resource inputs used in working in CEA. Decision models are typically used production of healthcare. [66] This within-country va-when the evidence base from the trial(s) of interest is riation is likely to be particularly pronounced in available exclusively in summary format. [22] Howlarge and economically heterogeneous countries. ever, there are examples where IPD from a single Clinical practice and conventions are also known to multinational trial have also been used -in combidiffer widely between (and within) coun-nation with non-trial IPD -to populate a decision tries.
[42, 45, 46, 56, 59, 62, 64, 67, 68] model with the objective to generate cost-effectiveness estimates for a country different from the one
Wider Socioeconomic Factors
where the trial had been carried out. Regressionbased methods, on the other hand, are used mainly Other factors that may have an impact on the when the country of interest actively recruited pageneralisability of CEA results from country to tients into the trial and the analyst has access to the country relate to variation between locations in study IPD (or at least country-specific summary terms of more general socioeconomic factors. The data). willingness (and ability) of a region/country to It emerges that the answers to the questions posed devote resources to healthcare is one of these fac-above depend, therefore, upon whether the country tors. Another broader factor discussed by Bernie of interest participated in the trial and whether IPD O'Brien [11] relates to the variation in health-related from the trial are available. To structure the discuspreferences between populations, such as those re-sion in a logical way, we propose an algorithm flected in health state utilities used to calculate (figure 1) developed to assist the decision as to QALYs.
which analytical strategy to adopt when faced with the task of generating country-specific cost-effec-2. Methods to Make Cost-Effectiveness tiveness estimates. Estimates More Country-Specific? to complete a multinational trial-based CEA, it seems reasonable -from the viewpoint of both the Consider that despite the IPD from the multinaindustry and national/state governments -to support tional (multicentre) trial being available, the country the use of methods which facilitate the 'translation' of interest did not participate in the trial. Decision of cost-effectiveness data obtained from one country makers in the country of interest will be interested in to another. The need to customise the economic the extent to which the results from this trial apply to study results to a specific jurisdiction is not purely their own setting. In this case, some form of decision academic, but stems from the need of decision mak-modelling to extrapolate the study results from one ers for context-specific information. This raises two country to another will be required. This is a very over-arching methodological questions: common situation in health technology assessment Algorithm to decide which methodology should be used to explore between-country differences in cost effectiveness. CEA = costeffectiveness analysis.
(HTA), and there are various examples in the litera-interest observed in the trial (e.g. relative reduction ture (see relevant chapters in the reviews by in risk of deaths, myocardial infarction, adverse Sculpher et al. [7] and Goeree et al. [8] ). effects), is then applied to the reference (baseline) risk -i.e. the event rate without the treatment -for As discussed in section 1, it is possible not only the country of interest. The latter information can be for resource use and cost data to vary by location, but the same can apply to clinical data. In the ascertained either from long-term follow-up cohort applied work, analysts have addressed this issue by studies, or (more practically) using existing risk assuming that the baseline risks for particular equations assuming that the risk factors (e.g. age, clinical events are location-specific, whilst the rela-tobacco consumption) between the trial population tive treatment effect is more generalisable across and that in the country of interest are the same, locations. [69] In this case it is considered good prac-regardless of the country. [70] Different distributions tice to develop an 'events-based model' built around of these risk factors in different countries will trans-'generalisable' features of the disease or patients' late into differences in country-specific baseline prognosis, and use the IPD from the trial to estimate risks. Because cost effectiveness is essentially conthe likelihood of occurrence of the clinical events of cerned with absolute differences (in costs and efinterest which are expected to have an impact on fects), the absolute number of events avertresource use and/or health-related QOL. The trialed -should this be the measure of clinical outwide relative treatment effect such as, for instance, the relative risk reduction (RRR) in the event(s) of come -in the new country is simply obtained by multiplying the trial-wide treatment effect by the WOSCOP trial IPD, considering a set of risk factors baseline event rate in the country of interest.
(e.g. age, high diastolic blood pressure, smoking). Parameter estimates from the exponential regression A well known example of this methodology is the model were then applied to IPD on the same set of application of the West of Scotland Coronary Prerisk factors obtained from a Belgian epidemiologivention Study (WOSCOPS) cost-effectiveness recal study, to predict individual-patient (and average) sults [71] to Belgium, [70] Canada, Sweden and South probabilities of cardiovascular events for the cohort Africa. [72] WOSCOPS [73] concluded that treatment in the model. [70] For each cardiovascular event conwith pravastatin reduced the risk of first-time heart sidered in the model, direct costs were estimated attack and death in middle-aged hypercholesterousing a registry which included 35% of the hospitallaemic men. Because of the increased risk of cardioisations in Belgium. Similarly, local data were used vascular disease (CVD) in the Scottish male populato estimate drug costs, while mortality tables for tion, though, the authors were keen to address possiBelgium were used to extrapolate long-term survivble concerns regarding the generalisability of the al. study findings to other countries. Using a system of It should be pointed out that this approach can competing risk equations, Caro et al. [70] combined also be used where the country of interest participattrial (i.e. RRR of cardiovascular events) and noned in the trial, but IPD are only available for the trial IPD (i.e. baseline event rates based on risk clinical outcome (i.e. no country-specific resource equations and risk factor distribution for Belgium, use data collection for the country of interest had and local costs and life expectancy) within a decitaken place). Furthermore, when the researcher is sion-analytic model to estimate the cost effectiveinterested in the cost effectiveness of the intervenness of pravastatin in Belgium. A simplified struction in particular subgroups of patients the analysis ture of their model is represented in figure 2.
above would need to be run separately for different At any point in time, men with hypercholesterorisk groups (based on the regression results). laemia were assumed to be either: (i) alive without experiencing cardiovascular events (and still be at The class of models discussed in section 2.1 tancy was estimated); or (iv) dead following a cartypically relies on the (often untested) assumption diovascular event. Parameter estimates from the risk that the relative clinical efficacy is independent of equations governing the above transitions in a poputhe disease underlying baseline risk, and that while lation not receiving the active treatment were obthe latter captures a range of country-specific factors tained by applying an exponential regression to the (e.g. epidemiology, medical attitude) the relative clinical effectiveness of the intervention does not differ greatly across countries. [45] The use of clinical data collected from different countries (centres) to estimate a single relative treatment effect on clinical outcomes is therefore an accepted practice. [74] However, as recognised by Caro et al., [70, 72] it is possible that between-country variability in the risk factors could lead to different cost effectiveness results in different locations. Between-country differences in the distribution of individual-patient level risk factors (e.g. age, smoking status, blood pressure) are always likely to exist, which when paired with pos- , [70] with permission). CVD = cardiovascular disease.
sible differences in country-specific factors (e.g. regarding the generalisability of the data from the trial. Their results emphasised the differing spread type of healthcare system, percentage of national of estimates that could be obtained under different GDP spent on healthcare) could limit the generalapproaches. The authors compared: isability of the relative treatment effect observed in the trial.
• a fully pooled analysis with multinational costing, which produced a single cost-effectiveness Despite these considerations, the assumption reestimate for the whole trial, assuming trial-wide garding the generalisability of the relative treatment effectiveness; effect on the clinical outcome from one country (or a
• a pooled analysis (for each country) with price set of countries) is only rarely scrutinised, [7] even weights from the individual countries again aswhen access to IPD from the multinational trial is suming trial-wide effectiveness, and which pronot an issue. When assessed, it is done so using a test duced very little variability in the results; of country-by-treatment interaction, [75] despite the fact that this test is typically underpowered. [23, 76] In • a strategy relating trial-wide effectiveness and the 'absence of evidence' (which does not imply country specific costs (with countries' own price 'evidence of absence') about between-country hetweights), which provided a much greater spread; erogeneity in the data, the results of this test are used and as a basis to justify the analysis of the pooled • the fully split analysis, which entailed splitting (clinical and resource use) data, [76] regardless of the the data and running a series of regression analycountry of origin. The implication is that non-statisses for each country independently from the tically significant between-country differences in others, resulted in the widest between-country relative treatment effect should not be a concern for variation. a given country decision maker, even when these are
The potential problem with this approach is that it qualitative in nature (i.e. the treatment effect in requires a choice to be made between 'pooling' different countries not only differs in magnitude but versus 'splitting'. The limitations of a pooled analyalso in direction).
sis have been discussed already. Splitting the data, It can be argued, though, that the presence of on the other hand, is impractical when the country of between-country differences in the magnitude and interest has recruited a limited number of patients sometimes in the direction of the relative treatment compared with the rest of the countries in the trieffect is a fundamental consideration which, when al. [12] Furthermore, it can be argued that data collectpaired with international differences in factors af-ed from different countries (and patients) may share fecting resource use and costs, makes the estimate of some degree of similarity and that there may be cost effectiveness for a particular country based on advantages in trying to capture such similarities. the trial-wide relative treatment effect unreliable, One way to do this is to reflect the hierarchical even when individual risk factors (and their distribu-structure in the multinational data, inherent in the tions) are similar between countries. natural clustering arising from patients being recruited in specific countries and receiving treatment One of the earliest attempts to address the statistiin centres with different characteristics. cal analysis of multinational clinical trials for a costeffectiveness analysis was presented by Willke et
Various authors have explored the use of hieraral.
[77] Using a system of related regression equa-chical regression models [78] for the analysis of multions, the authors developed a novel approach to tinational (and multicentre) trial-based cost-effecexplore the between-country variability in the CEA tiveness data. [79] [80] [81] [82] [83] [84] A simple hierarchical model for results by looking at the treatment-by-country inter-cost (health outcomes) data can be described as actions in both effectiveness and costs. Willke et follows. Let Y ij be the observed cost (health outal. [77] presented the cost-effectiveness results for come) of individual i in country j, and tij be an five separate countries under different assumptions indicator variable taking values 0 (control) and 1 (intervention), identifying the treatment arm alloca-equation 2 assumes that the random effects are 'lation. The regression model for multinational cost-tent' variables with a specific distribution, repreeffectiveness data can be described as follows senting the potential departures that the country-(equation 1): specific effects could have from the overall mean. By assuming country effects as random, these models allow the country-specific estimates to be obtained using not only the data from the country of interest, but also the data from the other countries
that participate in the trial. In this sense [85] the esti-(Eq. 1) mates are said to be borrowing strength from each where the coefficients αj and βj are the country j other. Willan et al. [79] showed how this class of mean cost in the control arm and the differential models can also be used to analyse multinational mean cost (health outcomes) between the two arms trial-based aggregate country-specific cost-effecof the trial, respectively, so that the mean cost in the tiveness data. Others [80] [81] [82] [83] [84] illustrated the application intervention group in country j is given by (αj + βj). of hierarchical regression models for costs and CEA The model can be re-written as (equation 2):
in the presence of trial-based IPD.
That the analysis based on IPD from multination-(Eq. 2) al trials offers more flexibility compared with the where the last three terms represent the random analysis based on aggregate country-specific data is components at the country (u j and vj) and individual undisputed. While allowing for the inclusion of a set (εij) level, usually assumed to follow a Normal of country-specific covariates, the aggregate level distribution with mean zero.
[78] data analysis does not facilitate inclusion of individThe terms α and β in equation 2 are overall ual-level covariates, which may lead in some cases (fixed) effects representing the trial-wide estimates, to the problem of 'ecological fallacy'.
3 The hierarwhile uj and vj are the 'random effects' representing chical model with IPD, on the other hand, offers the the jth country-specific departure from the overall potential to analyse the full dataset, hence the possimean cost in the control group (vj) and the differen-bility of accommodating both patient-and countrytial mean cost (uj).
2 Equation 2 allows the partition specific covariates. In particular, using both patientof the overall variability observed in the data into and country-level covariates, the hierarchical modtwo components, one associated with variation at elling can be particularly useful when attempting to patient-level (εij), and the other(s) associated with explain the observed between-country variability in variation at country level (uj and vj). Finally, the the results of multinational trial-based CEAs. Given parameter of interest, the country j specific mean the need to produce robust cost-effectiveness evidifference in mean cost (health outcomes) between dence for jurisdiction-specific decision making, it is the intervention and control arms is given by (β + only by incorporating both patient-and countryuj).
level covariates that potential between-country hetWith respect to the splitting approach, which erogeneity in the cost effectiveness of the intervenrequires a treatment-by-country interaction term, tion can be fully explored and accounted for.
2 Note that vj and uj are assumed to follow a bivariate Normal distribution, to reflect the fact that each country's mean cost in the control arm is correlated to the differential mean cost. In the analysis of the clinical data, this assumption would reflect the fact that the baseline events are correlated with the relative treatment effects. 3 This type of bias occurs when the relationship of relative treatment effect and patient averages across countries is not the same as the relationship for patients within countries. It may happen, for instance, that at a trial level a given treatment is clinically more effective (and cost effective) in younger patients. However, using average age in each country as a covariate for subgroup analysis will show no relationship between mean age and relative treatment effect if the distribution of the covariate age is similar across countries. [85, 86] Manca et al. [82] used hierarchical multivariate level covariates. In other words, the assumption that country-specific random effects are drawn from a models to reanalyse the economic data from a large common distribution may be erroneous. This critimultinational clinical study, ATLAS (Assessment cism can be addressed using the arguments proposed of Treatment with Lisinopril And Survival). This by Gelman et al., [89] who stated that: multinational trial enrolled 3164 patients in 19 countries, and compared low and high dose treatment "In virtually any statistical application, it is natwith the ACE inhibitor lisinopril in patients with ural to object to exchangeability on the grounds that chronic heart failure. Details of the main economic the units actually differ. […] The fact that the experand clinical analyses have been reported else-iments differ implies that the θjs differ, but it might where. [87, 88] This case study used a total of 3061 be perfectly acceptable to consider them as drawn observations (low dose, n = 1545; high dose, n = from a common distribution. […] Objecting to ex-1516) from 17 countries. The analysis reported here changeability for modelling ignorance is no more refers to the first 3 years of follow-up. Therefore, the reasonable than objecting to an iid [identically and specific results presented here are not to be considered an alternative of the main study report. [87] The authors compared the splitting and pooling approaches in the analysis of international cost-effectiveness data against the recently proposed use of hierarchical models. Figure 3 and figure 4 show the results of this analysis for the mean difference in costs (in British £) and survival gain (days), respectively, and compare the splitting and pooling approaches (a) against the hierarchical modelling strategy (b). It can be seen how the country-specific estimates (empty square markers) obtained using the splitting approach display a large dispersion around the overall mean (black circle marker) obtained using the pooling approach. The hierarchical regression model approach, on the other hand, produces country-specific estimates that are closer to the population mean (the black circle at the bottom of the graph on the right-hand side) compared with their counterparts in the analysis obtained by splitting the data. That is, the country-specific estimates in the hierarchical model borrow strength from each other. Some countries are more or less shrunk towards the overall mean. The degree of shrinkage is proportional to the between-and within-country variances, as well as the country-specific sample size. [81] One of the criticisms often made of the use of hierarchical models in multinational CEA is that this method may be inappropriate when we expect systematic differences between countries but are not able to 'explain' these adequately using country- 
distinguish different units should be encoded in the x and y [outcome] variables." (page 123).
As discussed in section 1, there are various factors that could explain the between-country variation in costs and effects differences observed between treatment arms in figure 3 and figure 4 . The re-analysis implemented here developed a Bayesian bivariate hierarchical regression model for cost and survival data in the trial, while controlling for a set of patient-and country-specific covariates.
[82] Figure 5 and figure 6 plot the country-specific differential cost and survival gain between treatment arms, respectively, against life expectancy at birth and the public expenditure in healthcare as a percentage of the national GDP. Both graphs indicate a positive relationship between the country-specific treatment effects and the country-specific covariate, suggesting that these factors may need to be accounted for when assessing the generalisability of the costeffectiveness results between countries.
IPD are Unavailable and the Country of Interest Did Not Participate in the Trial
A more challenging situation is when IPD are unavailable and the country of interest did not participate in the trial. Here the analyst has to rely on 
independently distributed] model for samples from a common population, objecting to regression models in general, or, for that matter, objecting to displaying points in a scatter plot without individual labels. As with regression, the valid concern is not about exchangeability, but encoding relevant knowledge as explanatory variables where possible." (page 124).
In essence this means that, 
"…the usual way to model exchangeability with covariates is through conditional independence … In this way exchangeable models become almost universally applicable, because any information to

Relating the Model to Clinical Practice
As mentioned in section 1.3, differences in clinical practice may be an important factor that needs to be accounted for when translating study results from one country to another. In developing the model for NICE, an important consideration therefore was how GPAs would be used in UK routine clinical practice. The evidence base contained two types of GPA trials: (i) those comparing the drugs with standard practice (i.e. management without GPAs) in all patients with non-ST elevation ACS regardless of whether a percutaneous coronary intervention (PCI) was subsequently undertaken (medical management); and (ii) those that looked at GPAs as an adjunct to PCI. Four treatment strategies were considered to be relevant for the UK, and the model was structured to compare all of them against each other. Lack of trial evidence comparing these strategies head-to-head was overcome by using 'evidence synthesis' methodology, such as indirect data published in the literature, and assume that the comparison. [91] Hence, it was necessary to re-strucrelative treatment effect estimated from other coun-ture the effectiveness data to reflect the nature of the indirect clinical comparison that was needed to poptries is indeed generalisable to the country of interulate the decision model. This was achieved by est. In this case, methods similar to those explained separating out the baseline event rates measured in in section 2.1 can be used, again supplementing the the standard therapy control groups in the trials from evidence base with additional IPD specific to the the treatment effect observed in the GPA arms relacountry of interest.
tive to the control group. The relative treatment The example here relates to an analysis undertak-effects for each treatment strategy were pooled en to inform the National Institute for Health and across the various groups of trials. [90] Clinical Excellence (NICE) on the cost effectiveness of using glycoprotein IIb/IIIa antagonists
Are Baseline Event Rates in the Trials
(GPAs) in the management of non-ST-elevation
Relevant to UK Practice?
ACS, and illustrates a real-life example of a decision
Given that the trials were undertaken largely model developed for the NICE. [90] In this section, outside the UK, the baseline event rates in patients we focus on the methods used in this example [7, 90] not having GPAs in the UK were considered to be and the steps followed in building the model. The potentially quite different to those in patients paper by Sculpher and Drummond [22] in this issue of randomised to the control groups in the trials. As PharmacoEconomics discusses the policy rationale mentioned in section 1, this could reflect differences behind this approach. There were several challenges in the epidemiology of the disease or, more probarelating to the generalisability of the data the authors bly, differences in overall management of patients had to deal with in building a model that was rele-with ischaemic heart disease (IHD) in the UK. After vant for the decision maker in the UK (i.e. the NHS). consulting with UK clinical experts, Palmer et al. [90] These challenges, together with the solutions adopt-considered the principal difference in the manageed to address them, are summarised in table I and ment of IHD in the UK compared with that in other reviewed in turn.
developed countries was that fewer patients were Table I . Challenges faced by Palmer et al. [90] in developing and analysing a cost-effectiveness model for the use of glycoprotein IIb/IIIa antagonists (GPAs) in the UK (reproduced from Sculpher et al., [7] with permission)
Limitation with trial data Methods used to overcome limitations Additional data source used Use of GPAs in the trials does not reflect their Four strategies relating to how GPAs are being range of possible uses in the UK used in the UK were identified with clinical collaborators Baseline event rates in trials unlikely to reflect Separate out baseline event rates in trial control UK-specific baseline event rates UK practice due to differences in management groups from relative treatment effects. Apply taken from PRAIS-UK, and a specific of ischaemic heart disease latter to UK-specific baseline event rates taken survey of patients undergoing acute from other sources PCI at Leeds General Infirmary
The relative treatment effect may also vary by Undertake a meta-regression to relate the location. In particular, the relative risk may be baseline (control group) risks with those in the related to the baseline risk in a location experimental (GPA) groups. If a clear relationship is identified, this can be used to adjust the relative risks used for a UK analysis to a level commensurate with UK baseline event rates
Recent changes in clinical practice in the UK Use of sensitivity analysis to assess the effect include the increased use of PCI and use of on the model's results of using baseline event clopidogrel as part of standard management.
rates from the trials instead of the UK However, the UK data sources may not reflect observational study. Also modelling a strategy of these changes, and their implications for the using clopidogrel as a fifth strategy in the model cost effectiveness of GPAs are unclear No data from the trials (UK-specific or Use of a long-term Markov model populated Transition probability and longer-term otherwise) to extrapolate short-term clinical using UK-specific observational data resource use data taken from the results to long-term QALYs NHAR NHAR = Nottingham Heart Attack Register; PCI = percutaneous coronary intervention; PRAIS-UK = Prospective Registry of Acute Ischaemic Syndromes in the UK.
considered for PCI at the time of the analysis. It was rameters from UK-specific data and applying the felt that the lower rates of PCI in the UK could have pooled relative treatment effects, for the alternative the effect of generating higher baseline event rates treatment strategies being considered relative to the than those observed in the literature. Secondly, the control (i.e. no use of GPAs), from the trials. This limited availability of 'acute' PCI (i.e. undertaken in amounts to assuming that baseline risks are not non-ST elevation patients shortly after presentation) transferable internationally, but RRRs are. It may in the NHS could cause clinicians to select ACS be, however, that the relative treatment effect is patients for acute PCI in a different way to that of itself related to baseline risk (e.g. the higher the clinicians in the GPA trials. Therefore, baseline baseline risk, the lower the treatment effect), in event rate data, which were specific to UK practice, which case the assumed independence between the were sought and information from the Prospective two components of clinical effectiveness is not susRegistry of Acute Ischaemic Syndromes in the UK tainable. It was therefore important to ascertain (PRAIS-UK), which is an observational cohort reg-whether any relationship existed between the relaistry of 1046 patients admitted to 56 UK hospitals tive treatment effect (i.e. RRR) and the baseline risk with ACS in 1999, was used.
observed in the literature. If that was the case, then this had to be built into the decision model in order sources) and the RRR estimated from the literature. In the absence of IPD from the trials of interest, one way of adapting the clinical results from interIn order to investigate whether the log relative national trials to the UK setting is by separating out risk in the individual trials varied with log baseline the baseline event rates associated with standard risk (i.e. the log event rate in the control group), a management (without GPAs), estimating those pa-random effects meta-regression model [92, 93] was used. 4 This form of meta-regression works by fitting scale for the group of trials relating to one of the a regression line between the event rates measured strategies considered in the model (i.e. GPA as part in the control groups of the trials and those of the of initial medical management). The results of the experimental (i.e. GPA) groups, with the number of analysis showed that there was a negative relationpoints from which the estimate is made being the ship between log baseline and log relative risk. This number of available trials. This function character-relationship was found to be not statistically signifiises the relationship between the baseline risks and cant, and the authors decided to estimate the RRR the relative risks. Once the function has been esti-using a meta-analysis. This choice was justified not mated in the meta-regression, the pooled relative only by the lack of statistical significance, but probrisk estimates from the trials could be adjusted ac-ably more realistically by: (i) the lack of evidence cording to the point on the regression line which directly relating to the baseline risk observed in the accords with the UK baseline risk. If the results studies included in the meta-regression with that suggest that a relationship exists, the decision model observed in the UK; and (ii) the inherent threats can be used to adjust the relative risk estimates involved in using meta-regression for clinical deciaccording to the baseline risk employed in the sion making. [94] [95] [96] model. Figure 7 shows the results of this meta-regresand Costs sion, plotting the relationship between baseline risk An important function of many decision models (in the control group) and relative risk -on the log is to extrapolate the effectiveness data available in trials.
Incorporating UK-Specific Resource Use
5 Palmer et al. [90] had the problem of taking the short-term effectiveness data in the available trials, which typically had a follow-up period of no more than 6 months, and extrapolate them to the lifetime time horizon of the typical patient. Therefore, a long-term (extrapolation) model was developed to estimate the future prognosis for patients who finished the short-term (6-month) model in one of two disease states: those having experienced a nonfatal myocardial infarction and those who had not but remained alive. The structure of the model is illustrated in figure 8 .
The long-term model took the form of a fourstate Markov process. The model assumed that at any point in time, patients could be in one of the following four states: (i) ischaemic heart disease (i.e. patients who had not experienced a nonfatal myocardial infarction); (ii) nonfatal myocardial infarction (not shown in figure 8 Markov model used to extrapolate results beyond trial duration; data from Nottingham Heart Attack Register [98] (n = 1279) used to derive UK costs of hospitalisation and procedures. IHD = ischaemic heart disease; MI = myocardial infarction.
tion (where surviving patients entered after 1 year several reasons for this, which mainly relate to the following an myocardial infarction); and (iv) death. perceived limitations of using evidence from a sinIt was necessary to be aware of the variation be-gle trial to inform decision making in a specific tween countries in long-term survival following car-jurisdiction (country). diac events. Transition probabilities were therefore It has been argued that most trials will not taken from a UK-specific observational study -the randomise individuals to all the relevant manageNottingham Heart Attack Register (NHAR). [98] Two ment options available in a specific healthcare syscohorts of patients (total n = 1279) with diagnoses tem. Furthermore, the period of follow-up in a trial indicative of ACS and follow-up data for up to 5 will often be shorter than the relevant time horizon years were used. In the context of the GPA model, for cost-effectiveness decisions; and finally, reliance the relevant 'events' estimated in the short-term on a single trial will often ignore other relevant model included revascularisation rates and days in evidence [100] [101] [102] [103] that is possibly more location-spehospital. For the longer term model, these events cific, which could be used to adapt the trial results to included myocardial infarctions, revascularisations the country of interest. While the use of (clinical and and days in hospital. In both cases these estimates of cost-effectiveness) evidence from a single multinaevent rates were based on data from the UK observa-tional (or multicentre) RCT to inform reimbursetional studies -PRAIS-UK [97] for the short-term ment decisions in a given country is still debatmodel and NHAR for the long-term model. All ed, [100, 102, 103] clinical trials will always play a crucial estimates of the costs of these events were then role in providing unbiased country-specific estitaken from UK sources. For further details about this mates of (clinical) treatment effects. [102] Key data on model the reader is invited to refer to the original the likelihood of particular events (e.g. adverse efpublications. [90, 99] fect, complications) and their relationship with quality of life and resource use implications in particular fundamental piece of information for healthcare decision makers. The evidence base concerning the The methods presented in section 2.3 may be a treatment strategy being examined could include sensible approach even when -although the trial several trials comparing various alternative treatproduces evidence directly relevant to the country of ment strategies, giving rise to a 'network of eviinterest [100] (e.g. the trial was carried out in, or dence'. In this case it is 'good practice' to synthesise included, the country of interest and a countryall the available evidence within a comprehensive specific estimate is available) -neither aggregate decision-analytic model, [90, 100, [102] [103] [104] [105] [106] ] the parameters (country-level) nor IPD are available. There are of which (e.g. treatment effect, transition probabili-decision-modelling methods in combination with ties) can be estimated through an evidence synthesis evidence synthesis techniques to overcome the lack model (e.g. indirect [107] [108] [109] or mixed treatment com-of IPD and produce cost-effectiveness estimates parison [91, 110, 111] ).
under specific assumptions (e.g. that the relative The difference with respect to the methodology treatment effect is generalisable between countries). described in section 2.3 is subtle. It is argued here Although the methods discussed in this paper that when the country of interest participated in one have been used mostly to inform decisions at nationor more of the trials that form the evidence base used al and state level, there are reasons to believe that to inform the estimation of the parameters used in they could be useful to inform policy decisions in the model, the synthesis model should include not jurisdictions within a given country/state (e.g. health only explanatory variables at the study-level, but maintenance organisations, regions in federalist also a country (or at the very least a geographical countries, general practitioner fund holding). area) indicator identifying where the study was carIt must be emphasised that the methodology in ried out. The model could be supplemented with this research area is currently under rapid developcountry-specific IPD on baseline risk, resource use, ment. However, various considerations can be made natural history of the disease, and mortality tables as in terms of recommendations for future research. explained in section 2.1.
Drummond et al. [9] provided a list of the main issues to consider in trial-and model-based cost-effective-3. Discussion ness analysis in relation to issues of generalisability. Methods enabling policy makers to assess the These included aspects relevant to the design, data extent to which trial (economic and clinical) results collection, analysis, and reporting of the study reare valid in different geographical settings should sults. have a key role in HTA. There are several reasons
The availability of IPD evidence external to the for this. First and foremost, reimbursement deci-trial referring to the country of interest is often sions are made at local (i.e. jurisdiction and country) paramount for an appropriate assessment of the levels. Furthermore, despite their interest in a set of generalisability from country to country, especially specific interventions, many healthcare systems (es-(but not exclusively) when the country of interest pecially in mid-income and developing countries) did not participate in the clinical study. It is argued are unable either to fund (or participate in) relevant that, in multinational trial-based CEA, patients and trials. Thirdly, the efficient use of research and country-specific covariates are essential for an accudevelopment funding for HTA at a country level rate assessment of the between-location variability requires the avoidance of duplication of funding of the cost-effectiveness results. While baseline paefforts supporting research questions already being tient-level data are routinely collected as part of a addressed in other jurisdictions. Given such a comtrial, this is not the case for country (centre) level plex scenario, decision makers need to be able to characteristics considered to have the potential to discern to what extent the observed variability in affect the generalisability of the study results. Quesclinical and cost-effectiveness results is country spetions that remain to be addressed include: (i) what cific and to what extent it is patient related. There is, country (centre) covariates should be collected; (ii) therefore, great value in developing methods that whether these can be routinely collected; and (iii) if enable decision makers to use international data to not, what alternative sources can be used. This congenerate jurisdiction-specific cost-effectiveness escern affects another element relevant during the timates. Several authors have attempted to address design phase of the study: the selection of countries the issue of how multinational trial-based cost-ef-(and centres) participating in the trial. Ideally this fectiveness data should be analysed, with different selection should be at random. Current methods of degrees of sophistication. Others have developed selection are unclear, but they probably reflect the always be useful for jurisdiction-specific resource level of funding for the cost-effectiveness study. allocation decisions. [9] Methods to reflect (and address) between-country differences in cost-effecIn terms of modelling methods available, it has tiveness data are available and are likely to develop been shown that hierarchical regression is a useful further. tool to analyse IPD collected alongside multinational trials. On the other hand, there are valid arguAcknowledgements ments for accepting that within-trial analysis is often not sufficient to appropriately inform reimburse- developments are expected.
Finally, in terms of reporting of the study results, References Drummond et al. [9] indicated that more transparency
